<DOC>
	<DOCNO>NCT02608346</DOCNO>
	<brief_summary>BRCA1 carrier high risk develop either relapse and/or new cancer growth include . These patient follow 30 month ( 2,5 year ) mutate TP53 mutation detection 42 month ( 3,5 year ) mutate TP53 mutation detection circulate tumor cell detection ( CTC ) perform hospital visit ( technical reason patient include Institut Curie propose participate CTC substudy ) .</brief_summary>
	<brief_title>Circulating Tumor DNA Follow-up BRCA1 Mutation Carriers ( CirCa 01 )</brief_title>
	<detailed_description />
	<criteria>1 . Patient evidence invasive tumor mass inclusion ( clinical , , radiological exam ) 2 . Carriers know germline BRCA1 deleterious mutation ( personal history cancer NOT mandatory ) . 3 . Age ≥ 30 year patient personal previous history cancer 4 . Age ≥ 40 year patient without personal previous history cancer 5 . Patient followup visit schedule include center least year 6 . Patient health care insurance 7 . Signed informed consent patient 1 . Patient present invasive tumor mass ( e.g . stage IV cancer localize cancer yet surgically remove ) 2 . Carriers germline BRCA1 variant unknown significance 3 . Carriers germline BRCA2 deleterious mutation variant 4 . Individuals low risk BRCA1related tumor growth , i.e . woman underwent prophylactic bilateral mastectomy AND adnexectomy . 5 . Any medical condition Investigator 's opinion render patient unsuitable study 6 . Patient deprive ability decide . 7 . Patient unable regular follow geographical , social psychological reason .</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Circulating tumor DNA</keyword>
	<keyword>BRCA1 mutation</keyword>
	<keyword>Circulating tumor cell</keyword>
</DOC>